82岁浙江富豪25亿股票分给两个女儿

Core Points - The ownership structure of Jiuzhou Pharmaceutical has changed, with Huaxuande no longer holding shares in Zhongbei Group and Taizhou Gede, leading to a new actual controller structure involving Huali Rong and Huaxiao Hui [2][3] - Jiuzhou Pharmaceutical reported a revenue of 4.16 billion yuan for the first three quarters of the year, reflecting a year-on-year growth of 4.92%, and a net profit of 748 million yuan, up 18.51% year-on-year [4] Group 1 - Huaxuande transferred 28.50% of Zhongbei Group's shares to Huali Rong and 14% to Huaxiao Hui, with total payments amounting to 61.815 million yuan [2] - Following the transfer, Huali Rong holds 22.17% and Huaxiao Hui holds 13.36% of Jiuzhou Pharmaceutical indirectly [2] - The market value of Jiuzhou Pharmaceutical shares held by Zhongbei Group and Taizhou Gede is estimated at approximately 24.76 billion yuan [2] Group 2 - Jiuzhou Pharmaceutical, established in July 1998, is a technology-driven CDMO enterprise focusing on small molecule drugs, peptide drugs, conjugated drugs, and small nucleic acid drugs [3] - Huaxuande, aged 82, stepped down as chairman in 2014, with his daughter Huali Rong succeeding him [3] - Huali Rong has held various leadership roles and was recently elected as the executive director and legal representative of Jiuzhou Pharmaceutical [3] Group 3 - Huaxuande and his family's wealth was ranked 338th on the Hurun Rich List in 2020 with 16 billion yuan, and they are currently ranked 2750th and 940th on the global and national rich lists, respectively [4] - As of November 13, Jiuzhou Pharmaceutical's stock price increased by 2.11% to 20.34 yuan per share, with a market capitalization of 18.091 billion yuan [4]